Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Nls Pharmaceutics Ltd WT (NLSPW)

Nls Pharmaceutics Ltd WT (NLSPW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger PR Newswire - Thu Oct 30, 3:15PM CDT

Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol "NCEL"

NLSPW : 0.0179 (-3.24%)
NLS : 0.8204 (+11.20%)
NCEL : 2.91 (-12.61%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs PR Newswire - Thu Oct 30, 6:00AM CDT

ZURICH , Oct. 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem PR Newswire - Wed Oct 29, 5:00AM CDT

ZURICH , Oct. 29, 2025 /PRNewswire/ --  NLS Pharmaceutics Ltd.  (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares PR Newswire - Wed Oct 29, 2:53AM CDT

ZURICH and NESS ZIONA, Israel , Oct. 29, 2025 /PRNewswire/ --  NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and  Kadimastem Ltd. (TASE: KDST) ("Kadimastem")...

NLSPW : 0.0179 (-3.24%)
KMSTF : 5.0600 (-0.78%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies PR Newswire - Mon Oct 27, 6:00AM CDT

The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025 PR Newswire - Thu Oct 23, 5:01AM CDT

ZURICH , Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.  (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement ACCESS Newswire - Mon Mar 31, 4:10AM CDT

The equity financing is at a 10% premium to the market share price1

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics CEO Issues Letter to Shareholders ACCESS Newswire - Wed Dec 11, 2024

ZURICH, SWITZERLAND / ACCESSWIRE / December 11, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders ACCESS Newswire - Tue Dec 3, 2024

ZÜRICH, SWITZERLAND / ACCESSWIRE / December 3, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) (NLS), a biopharmaceutical company, is pleased to share preclinical data demonstrating the potential...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence ACCESS Newswire - Mon Oct 21, 2024

ZURICH, SWITZERLAND / ACCESSWIRE / October 21, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to developing...

NLSPW : 0.0179 (-3.24%)
NLSP : 7.6200 (+2.97%)

Barchart Exclusives

Inflation Data, AI Earnings and Other Can't Miss Items this Week Barchart - Sun Dec 14, 12:00PM CST
Markets enter a critical week still reeling from Friday's sharp selloff in technology and AI stocks following disappointing reactions to Oracle and Broadcom earnings that raised questions about AI infrastructure spending sustainability and return on massive capital investments. Here are 5 things to watch this week in the Market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot